Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
J Arthroplasty. 2023 Jun;38(6S):S350-S354. doi: 10.1016/j.arth.2023.03.076. Epub 2023 Apr 1.
The role of medications to prevent arthrofibrosis following total knee arthroplasty (TKA) remains unclear. We investigated the effect of common oral medications with reported antifibrotic properties on preventing arthrofibrosis and manipulation under anesthesia (MUA) following primary TKA.
Using our total joint registry, 9,771 patients (12,735 knees) who underwent TKA with cemented, posterior-stabilized, and metal-backed tibial components from 2000 to 2016 were identified. Arthrofibrosis, defined as range of motion (ROM) ≤90° for ≥12 weeks postoperatively or as ROM ≤90° requiring MUA, was diagnosed in 454 knees (4%) and matched 1:2 to controls. Mean age was 62 years (range, 19 to 87) and 57% were women. The majority of operative diagnoses were osteoarthritis. Perioperative use of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins), angiotensin converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers (ARBs), oral corticosteroids, antihistamines, and nonsteroidal anti-inflammatory drugs (NSAIDs) were manually confirmed. Medication effect in preventing arthrofibrosis and MUA was assessed using adjusted multivariable analyses. Mean follow-up was 8 years (range, 2 to 20).
Reduced risk of arthrofibrosis was associated with perioperative NSAID use (odds ratio (OR) 0.67, P = .045). A similar trend was observed with perioperative corticosteroids (OR 0.52, P = .098). Corticosteroids were associated with reduced risk of MUA (OR 0.26, P = .036), and NSAIDs trended towards reducing MUA (OR 0.69, P = .11).
This investigation determined that perioperative NSAID use was associated with reduced risk of arthrofibrosis and trended towards reduced risk of subsequent MUA. Similarly, oral corticosteroids were associated with reduced risk of MUA and trended towards reduced risk of arthrofibrosis.
在全膝关节置换术(TKA)后,药物预防关节纤维化的作用仍不清楚。我们研究了具有报道的抗纤维化特性的常见口服药物对预防原发性 TKA 后关节纤维化和麻醉下手法松解(MUA)的影响。
使用我们的关节置换登记处,确定了 2000 年至 2016 年间接受骨水泥固定、后稳定、金属背衬胫骨组件的 TKA 治疗的 9771 名患者(12735 膝)。关节纤维化的定义为术后 12 周内关节活动度(ROM)≤90°或 ROM≤90°需要 MUA,共 454 膝(4%)被诊断为关节纤维化,并与对照组 1:2 匹配。平均年龄为 62 岁(19 至 87 岁),57%为女性。大多数手术诊断为骨关节炎。使用 3-羟基-3-甲基戊二酰辅酶 A 还原酶抑制剂(他汀类药物)、血管紧张素转换酶抑制剂(ACE 抑制剂)、血管紧张素 II 受体阻滞剂(ARB)、口服皮质类固醇、抗组胺药和非甾体抗炎药(NSAIDs)的围手术期使用情况由手动确认。使用调整后的多变量分析评估药物预防关节纤维化和 MUA 的效果。平均随访时间为 8 年(2 至 20 年)。
围手术期使用 NSAIDs 与关节纤维化风险降低相关(比值比(OR)0.67,P=0.045)。围手术期使用皮质类固醇也有类似的趋势(OR 0.52,P=0.098)。皮质类固醇与 MUA 风险降低相关(OR 0.26,P=0.036),而 NSAIDs 则降低 MUA 的趋势(OR 0.69,P=0.11)。
本研究发现,围手术期使用 NSAIDs 与关节纤维化风险降低相关,且与随后 MUA 风险降低相关。同样,口服皮质类固醇与 MUA 风险降低相关,且与关节纤维化风险降低相关。